Rolnick A, Lubow RE. Why is the driver rarely motion sick? The role of controllability in motion sickness. Gahlinger PM. Cabin location and the likelihood of motion sickness in cruise ship passengers.
J Travel Med. The effectiveness of a motion sickness counselling programme. Br J Clin Psychol. Behavioral methods of alleviating motion sickness: effectiveness of controlled breathing and a music audiotape.
Reduction of motion sickness with an enhanced placebo instruction: an experimental study with healthy participants. Psychosom Med. Eden D, Zuk Y. Seasickness as a self-fulfilling prophecy: raising self-efficacy to boost performance at sea. J Appl Psychol. Effect of temporal relationship between respiration and body motion on motion sickness. Spinks A, Wasiak J. Scopolamine hyoscine for preventing and treating motion sickness.
Cochrane Database Syst Rev. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study. Clin Neuropharmacol. Airsickness prevention in helicopter passengers. Br J Pharmacol Chemother. Comparison of marezine and dramamine in preventing symptoms of motion sickness.
Motion-sickness medications for aircrew: impact on psychomotor performance. Sherman CR. Motion sickness: review of causes and preventive strategies. Vertigo and motion sickness. Part II: pharmacologic treatment. Ear Nose Throat J. Gordon CR, Shupak A. Prevention and treatment of motion sickness in children. CNS Drugs. Sedation and antihistamines: an update.
Review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol. Transdermal scopolamine for prevention of motion sickness: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet. Safety of double-dose transdermal scopolamine. Failure of cetirizine and fexofenadine to prevent motion sickness. Ann Pharmacother. Diazepam as an anti-motion sickness drug. J Otolaryngol. Rizatriptan reduces vestibular-induced motion sickness in migraineurs.
J Headache Pain. High dose ondansetron for reducing motion sickness in highly susceptible subjects. Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea. Ginger root against seasickness. A controlled trial on the open sea. Acta Otolaryngol. P6 acupressure increases tolerance to nauseogenic motion stimulation in women at high risk for PONV. Can J Anaesth. This content is owned by the AAFP.
A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv aafp. Scopolamine patches may cause other side effects.
Call your doctor if you have any unusual problems while you are using this medication. Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture not in the bathroom.
Store patches in an upright position; do not bend or roll them. It is important to keep all medication out of sight and reach of children as many containers such as weekly pill minders and those for eye drops, creams, patches, and inhalers are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location — one that is up and away and out of their sight and reach.
Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. In case of overdose or if someone swallows a scopolamine patch, call your local poison control center at If the victim has collapsed or is not breathing, call local emergency services at Before having any laboratory test, tell your doctor and the laboratory personnel that you are using scopolamine patch.
Do not let anyone else use your medication. Ask your pharmacist any questions you have about refilling your prescription. It is important for you to keep a written list of all of the prescription and nonprescription over-the-counter medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements.
You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies. Motion sickness, the discomfort experienced when perceived motion disturbs the organs of balance, may include symptoms such as nausea, vomiting, pallor, cold sweats, hypersalivation, hyperventilation and headaches.
The control and prevention of these symptoms has included pharmacological, behavioural and complementary therapies. Although scopolamine hyoscine has been used in the treatment and prevention of motion sickness for decades, there have been no systematic reviews of its effectiveness. To assess the effectiveness of scopolamine versus no therapy, placebo, other drugs, behavioural and complementary therapy or two or more of the above therapies in combination for motion sickness in persons both adults and children without known vestibular, visual or central nervous system pathology.
The date of the most recent search was 14 April All parallel-arm, randomised controlled trials RCTs focusing on scopolamine versus no therapy, placebo, other drugs, behavioural and complementary therapy or two or more of the above therapies in combination. We considered outcomes relating to the prevention of onset or treatment of clinically-defined motion sickness, task ability and psychological tests, changes in physiological parameters and adverse effects.
Two authors independently extracted data from the studies using standardised forms. Data collection and analysis: Data from the studies were extracted independently by two authors using standardised forms. Study quality was assessed. Dichotomous data were expressed as odds ratio OR and a pooled OR was calculated using the random effects model.
Main results: Of 27 studies considered potentially relevant, 12 studies enrolling subjects met the entry criteria. Scopolamine was administered via transdermal patches, tablets or capsules, oral solutions or intravenously.
Scopolamine was compared against placebo, calcium channel antagonists, antihistamine, meth-scopolamine or a combination of scopolamine and ephedrine.
0コメント